3T2N

Human hepsin protease in complex with the Fab fragment of an inhibitory antibody

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.55 Å
  • R-Value Free: 0.275 
  • R-Value Work: 0.242 
  • R-Value Observed: 0.244 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history. 


Literature

Allosteric antibody inhibition of human hepsin protease.

Koschubs, T., Dengl, S., Durr, H., Kaluza, K., Georges, G., Hartl, C., Jennewein, S., Lanzendorfer, M., Auer, J., Stern, A., Huang, K.S., Packman, K., Gubler, U., Kostrewa, D., Ries, S., Hansen, S., Kohnert, U., Cramer, P., Mundigl, O.

(2012) Biochem J 442: 483-494

  • DOI: 10.1042/BJ20111317
  • Primary Citation of Related Structures:  
    3T2N

  • PubMed Abstract: 

    • Hepsin is a type II transmembrane serine protease that is expressed in several human tissues. Overexpression of hepsin has been found to correlate with tumour progression and metastasis, which is so far best studied for prostate cancer, where more than 90% of such tumours show this characteristic ...

    Hepsin is a type II transmembrane serine protease that is expressed in several human tissues. Overexpression of hepsin has been found to correlate with tumour progression and metastasis, which is so far best studied for prostate cancer, where more than 90% of such tumours show this characteristic. To enable improved future patient treatment, we have developed a monoclonal humanized antibody that selectively inhibits human hepsin and does not inhibit other related proteases. We found that our antibody, hH35, potently inhibits hepsin enzymatic activity at nanomolar concentrations. Kinetic characterization revealed non-linear, slow, tight-binding inhibition. This correlates with the crystal structure we obtained for the human hepsin-hH35 antibody Fab fragment complex, which showed that the antibody binds hepsin around α3-helix, located far from the active centre. The unique allosteric mode of inhibition of hH35 is distinct from the recently described HGFA (hepatocyte growth factor activator) allosteric antibody inhibition. We further explain how a small change in the antibody design induces dramatic structural rearrangements in the hepsin antigen upon binding, leading to complete enzyme inactivation.

    Organizational Affiliation: 

    Gene Center Munich, Department of Biochemistry, Ludwig-Maximilians-Universität München, Munich, Germany.



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Serine protease hepsin A, B372Homo sapiensMutation(s): 0 
Gene Names: HPN, TMPRSS1
EC: 3.4.21.106
Find proteins for P05981 (Homo sapiens)
Explore P05981 
Go to UniProtKB:  P05981
NIH Common Fund Data Resources
PHAROS:  P05981
GTEx:  ENSG00000105707
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetailsImage
Antibody, Fab fragment, Heavy Chain H, I225Homo sapiensMutation(s): 0 
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetailsImage
Antibody, Fab fragment, Light Chain L, M215Homo sapiensMutation(s): 0 
Protein Feature View
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.55 Å
  • R-Value Free: 0.275 
  • R-Value Work: 0.242 
  • R-Value Observed: 0.244 
  • Space Group: P 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 62.98α = 88.71
b = 66.58β = 94.3
c = 108.33γ = 104.53
Software Package:
Software NamePurpose
PHASERphasing
BUSTERrefinement
XDSdata reduction
XSCALEdata scaling

Structure Validation

View Full Validation Report


View more in-depth experimental data

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2011-12-28
    Type: Initial release
  • Version 1.1: 2012-04-18
    Changes: Database references
  • Version 1.2: 2012-07-25
    Changes: Other